| Project/Area Number |
16K10511
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Fukushima Medical University |
|---|
Principal Investigator |
Kono Koji 福島県立医科大学, 医学部, 教授 (40283204)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
中島 隆宏 福島県立医科大学, 医学部, 博士研究員 (90567447)
|
|---|
| Project Period (FY) |
2016-04-01 – 2020-03-31
|
| Project Status |
Completed (Fiscal Year 2019)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2018: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Keywords | 免疫チェックポイント阻害 / 消化器癌 / Nivolmab / PD-L1 / 免疫チェックポイント阻害剤 / 消化器がん / 免疫チェックポイント / 免疫チョックポイント阻害剤 / IFN-gamma / 癌免疫療法 / PDL1 / PD1 |
|---|
| Outline of Final Research Achievements |
(I)PD-L1 is upregulated by IFN-g through JAK-STAT pathway in GI-tract cancer.(II)There is a positive correlation between EMT status and PD-L1 expression in GI tract cancer.(III)microRNA from tumor microenvironment can down-regulate PD-L1 expression in colon cancer
|
| Academic Significance and Societal Importance of the Research Achievements |
消化器癌におけるPD-L1の発現調節機構を解明することで、免疫チェックポイント阻害剤の効果増強、ResponderのPrediction、Non-responderの機序解明に寄与できる。
|
